Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02520752
Title A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Midazolam

Capmatinib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP

Facility Status City State Zip Country Details
Emory University School of Medicine/Winship Cancer Institute SC-2 Atlanta Georgia 30322 United States Details
Washington University School of Medicine Saint Louis Missouri 63110 United States Details
Novartis Investigative Site Sofia 1756 Bulgaria Details
Novartis Investigative Site Copenhagen DK-2100 Denmark Details
Novartis Investigative Site Dijon Cedex Cote D Or 21034 France Details
Novartis Investigative Site Pierre Benite 69310 France Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Barcelona Catalunya 08003 Spain Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Santiago de Compostela Galicia 15706 Spain Details
Novartis Investigative Site London W12 0HS United Kingdom Details
Novartis Investigative Site Manchester M20 9BX United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field